Dr. Siemionow, who successfully performed the first human facial transplant in the United States in Dec. 2008, is the first U.S. physician to receive Institutional Review Board approval for facial transplantation surgery. She received her medical degree from the Poznan Medical Academy in Poland, where she completed her residency in orthopedics and earned her PhD in microsurgery, according to the release.
Dr. Siemionow and her team at Cleveland Clinic completed the early pre-clinical work during the development of dermaPACE, SANUWAVE’s lead product, which is currently in an Investigational Device Exemption clinical trial evaluating Pulsed Acoustic Cellular Expression (PACE) technology and the safety and efficacy of dermaPACE for its first indication, the healing of diabetic foot ulcers, according to the release. SANUWAVE intends to apply its proprietary technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions.
Dr. Siemionow is a paid consultant for SANUWAVE.
Read the release on Dr. Maria Siemionow (pdf).
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
